Monday, February 10
10:30 am Conference Program Registration
11:50 Chairperson's Opening Remarks
Julien N. Bradley, MBA, Senior Director, Sales & Marketing, Quanterix Corporation
12:00 pm KEYNOTE PANEL DISCUSSION:
Moderator: Jill Hagenkord, M.D., CMO & Senior Vice President, InVitae
Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP (2014 AMP President and 2013 AMP Economic Affairs, Professional Relations, Strategic Opportunities Committees)
Chris L. Jagmin, M.D., Senior Medical Director, National Medical Policy and Operations, Aetna
- Overview of CPT codes
- Transitioning to the molecular pathology codes from the clinical laboratory’s perspective
- Understanding rationale behind new CPT codes
1:00 Session Break
1:15 Luncheon Presentation I: Simoa HD-1: A Fully Automated, Multiplexed Immunoanalyzer with Single Molecule Sensitivity
David C. Duffy, Ph.D., CTO, Quanterix Corporation
Single Molecule Array (Simoa) technology allows multiple proteins to be detected at concentrations 1000-fold lower than currently possible. Simoa is based on the capture of single molecules on paramagnetic beads, and their detection in arrays of femtoliter wells. We will illustrate the power of this analytical sensitivity in diagnosing cancer, neurological diseases, and infectious diseases using the Simoa HD-1 Analyzer, a fully automated instrument designed for use in clinical research and diagnosis.
1:45 Luncheon Presentation II (Sponsorship Opportunity Available)
2:15 Session Break
2:30 PANEL DISCUSSION: Opportunities and Challenges in Commercializing Esoteric Diagnostics
Moderator: Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
Organized by the Personalized Medicine Coalition, this panel will outline both the promise and the pitfalls in bringing new molecular diagnostics to market, including the scientific, regulatory, payment, and adoption issues that innovative diagnostics companies must negotiate. Featuring leaders in the field, it will provide insight into best practices and likely scenarios for future trends.
Laura Brege, MBA, CEO, Nodality, Inc.
Peter Maag, Ph.D., CEO, XDx, Inc.
Jay Wohlgemuth, M.D., Senior Vice President, Science & Innovation, Quest Diagnostics
Alan Wright, M.D., MPH, CMO, Roche Diagnostics
3:45 Next-Gen Sequencing for Prostate Cancer
Philip D. Cotter, Ph.D., FACMG, FFSc(RCPA), Principal, ResearchDx
Diagnostic and prognostic assessment of prostate cancer has been dramatically improved by the use of new laboratory technologies. This presentation focuses on the use of gene panel and pathway analyses using Next-Gen sequencing approaches in prostate cancer.
4:00 Models for the Development of Multiplex Companion Diagnostics
Austin Tanney, Ph.D., Scientific Liaison Manager, Almac
4:15 A Bioinformatics Framework for Clinical Research Sequencing
Daniel Rhodes, Ph.D., Head, Medical Science Informatics, Life Technologies
The widespread adoption of precision medicine in oncology requires: a compendium of therapies targeting the genetic vulnerabilities of cancer; the diagnostic tools capable of generating a precise molecular diagnosis; and importantly, the information systems to connect a patient’s molecular diagnosis to optimal treatment hypotheses. Here, we will present Life Technologies’ work to accelerate (1) defining the landscape of actionable driver genetic events in cancer, (2) developing a next-generation sequencing screen on the Ion Torrent semiconductor-sequencing platform, (3) assembling treatment-related information relevant for clinical research, and (4) devising a turnkey bioinformatics solution to democratize clinical sequencing in the future.
4:30 Refreshment Break and Transition to Plenary Keynote
6:15 Grand Opening Reception in the Exhibit Hall with Poster Viewing
7:45 Close of Day
Day 1 | Day 2 | Day 3 | Download Brochure